The power to save the planet is inside us all – how to get past despair to powerful action on climate change
Our species is in a race with climate change, and a lot of people want to know, 'Can I really make a difference?'
The question concerns what's known as agency. Its meaning is complex, but in a nutshell it means being able to do what you set out to do and believing you can succeed.
How well people exercise their agency will determine the severity of global warming – and its consequences.
The evidence is clear that people are changing the climate dramatically. But human actions can also affect the climate for the better by reducing fossil fuel burning and carbon emissions. It's not too late to avert the worst effects of climate change, but time is running out.
Despite abundant technical agency, humanity is alarmingly short of psychological agency: belief in one's personal ability to help. A 10-country survey study in the Lancet, a British medical journal, found that more than half of young people ages 16-25 feel afraid, sad, anxious, angry, powerless and helpless about climate change.
As professors, we bring complementary perspectives to the challenges of taking action on climate change. Tom Bateman studies psychology and leadership, and Michael Mann is a climate scientist and author of the 2022 book 'The New Climate War.'
Human activities – particularly relying on coal, oil and natural gas for energy – have dramatically affected the climate, with dire consequences.
As greenhouse gases from burning fossil fuel use accumulate in the atmosphere, they warm the planet. Rising global temperatures have fueled worsening heat waves, rising sea levels and more intense storms that become increasingly harder to adapt to. A new report from the Intergovernmental Panel on Climate Change describes some of the dangerous disruptions already underway, and how they are putting people and the environment at risk.
Just like humans can choose to drive gas-guzzlers, they can also choose to act in ways that influence the climate, air quality and public health for the better. Scientific knowledge and countless opportunities for action make that agency possible.
A key part of agency is one's belief, when faced with a task to perform, a situation to manage, or a long-term goal like protecting the climate, that 'I can do this.' It's known as self-efficacy.
This may be the most important psychological factor in predicting how well people will cope with both climate change and COVID-19, recent online survey data from Europe indicate. People feeling adequate agency are more likely to persevere, rebound from setbacks and perform at high levels.
With climate change, a high sense of self-efficacy strengthens a person's willingness to reduce carbon emissions (mitigation) and prepare for climate-related disasters (adaptation). Studies confirm this for actions including volunteering, donating, contacting elected officials, saving energy, conserving water during extreme weather, and more.
To build agency for something that can feel as daunting as climate change, focus first on the facts. In the case of climate change: Greenhouse gas emissions cause the most harm, and people can help far more than they realize.
Successful agency has four psychological drivers, all of which can be strengthened with practice:
1) Intentionality: 'I choose my climate goals and actions for high impact.'
Deciding to act with purpose—knowing what you intend to do–is far more effective than thinking 'My heart's in the right place, I just have to find the time.'
In the big picture, one's highest climate efficacy is in participating in larger efforts to stop fossil fuel use. People can set specific ambitious goals for reducing personal and household energy use and join others in collective actions.
2) Forethought: 'I am looking ahead and thinking strategically about how to proceed.'
Knowing your goals, you can think strategically and develop an action plan. Some plans support relatively simple goals involving individual lifestyle changes, such as adjusting consumption and travel patterns. Wider reaching actions can help change systems – such as long-term activities that advocate for climate-friendly policies and politicians, or against policies that are harmful. These include demonstrations and voter campaigns.
3) Self-regulation: 'I can manage myself over time to optimize my efforts and effectiveness.'
Worrying about the future is becoming a lifelong task—off and on for some, constant for others. Climate change will cause disasters and scarcities, disrupt lives and careers, heighten stress and harm public health. Seeing progress and working with others can help relieve stress.
4) Self-reflection: ' I will periodically assess my effectiveness, rethink strategies and tactics, and make necessary adjustments.'
It's difficult to imagine a greater need for lifelong learning than as we navigate decades of climate change, its many harms and efforts by fossil fuel companies to obscure the facts. Reflection – or, more precisely, keeping up with the latest science, learning and adapting – is vital as the future keeps presenting new challenges.
Even seemingly minor first steps can help reduce carbon emissions and lead to paths of greater action, but individual actions are only part of the solution. Big polluters often urge consumers to take small personal actions, which can deflect attention from the need for large-scale policy interventions.
Individual agency should be seen as a gateway for group efforts that can more quickly and effectively change the trajectory of climate change.
'Collective agency' is another form of agency. A critical mass of people can create societal [tipping points] that pressure industry and policymakers to move more quickly, safely and equitably to implement policies that reduce greenhouse gas emissions.
Helping to elect local, state and national officials who support protecting the climate, and influencing investors and leaders of corporations and associations, can also create a sense of agency, known as 'proxy agency.'
[Over 150,000 readers rely on The Conversation's newsletters to understand the world. Sign up today.]
Together, these efforts can rapidly improve humanity's capacity to solve problems and head off disasters. Fixing the world's climate mess requires both urgency and a sense of agency to create the best possible future.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Thomas S. Bateman, University of Virginia and Michael E Mann, Penn State
Read more:
7 ways to get proactive about climate change instead of feeling helpless: Lessons from a leadership expert
A mild-mannered biker triggered a huge debate over humans' role in climate change – in the early 20th century
Pew's new global survey of climate change attitudes finds promising trends but deep divides
Michael E Mann receives grant funding for climate research from the National Science Foundation, Department of Energy, National Oceanographic and Atmospheric Administration
Thomas S. Bateman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Times
33 minutes ago
- New York Times
F.D.A. Looks to A.I. to Enhance Efficiency
The Food and Drug Administration is planning to use artificial intelligence to 'radically increase efficiency' in deciding whether to approve new drugs and devices, one of several top priorities laid out in an article published Tuesday in JAMA. Another initiative involves a review of chemicals and other 'concerning ingredients' that appear in U.S. food but not in the food of other developed nations. And officials want to speed up the final stages of making a drug or medical device approval decision to mere weeks, citing the success of Operation Warp Speed during the Covid pandemic when workers raced to curb a spiraling death count. 'The F.D.A. will be focused on delivering faster cures and meaningful treatments for patients, especially those with neglected and rare diseases, healthier food for children and common-sense approaches to rebuild the public trust,' Dr. Marty Makary, the agency commissioner, and Dr. Vinay Prasad, who leads the division that oversees vaccines and gene therapy, wrote in the JAMA article. The agency plays a central role in pursuing the agenda of the U.S. health secretary, Robert F. Kennedy Jr., and it has already begun to press food makers to eliminate artificial food dyes. The new road map also underscores the Trump administration's efforts to smooth the way for major industries with an array of efforts aimed at getting products to pharmacies and store shelves quickly. Some aspects of the proposals outlined in JAMA were met with skepticism, particularly the idea that artificial intelligence is up to the task of shearing months or years from the painstaking work of examining applications that companies submit when seeking approval for a drug or high-risk medical device. 'I don't want to be dismissive of speeding reviews at the F.D.A.,' said Stephen Holland, a lawyer who formerly advised the House Committee on Energy and Commerce on health care. 'I think that there is great potential here, but I'm not seeing the beef yet.' Want all of The Times? Subscribe.


Scientific American
an hour ago
- Scientific American
What a Wandering Mind Learns
While you do the dishes or drive to work, your mind is likely not on the task at hand; perhaps you're composing a grocery list or daydreaming about retiring in Italy. But research published in the Journal of Neuroscience suggests you might be taking in more than you think. During a simple task that requires minimal attention, mind wandering may actually help people learn probabilistic patterns that let them perform the task better. 'The idea to study the potentially beneficial influence of mind wandering on information processing occurred to us during the COVID pandemic, when we had plenty of time to mind wander,' says Péter Simor, lead author of the recent study and a psychology researcher at Eötvös Loránd University in Budapest. Study participants practiced a simple task in which they pressed keyboard buttons corresponding to the direction of arrows that lit up on a screen. But there were patterns hidden within the task that the participants were unaware of—and they learned these patterns without consciously noticing them. The researchers found that when participants reported letting their minds wander, they adapted to the task's hidden patterns significantly faster. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. 'This is an exciting and important piece of work, especially because the authors opted for a nondemanding task to check how [mind wandering] would affect performance and learning,' says Athena Demertzi, a cognitive and clinical neuroscientist at the University of Liège in Belgium. Previous related research focused more on long and demanding tasks, she says—on which zoning out is typically shown to have a negative effect. But the results are not clear-cut, says Jonathan Smallwood, a psychology researcher at Queen's University in Kingston, Ontario. 'I don't think that this means the spontaneous mind-wandering episodes themselves cause implicit learning to occur,' he says. 'Rather both emerge at the same time when people go into a particular state.' Neither Smallwood nor Demertzi was involved in the new study. Simor, who studies sleep, was interested in whether participants' mind wandering displayed any neural hallmarks of dozing off. Using electroencephalogram recordings, the team showed that in those test periods, participants' brains produced more of the slow waves that are dominant during sleep. Perhaps, the researchers say, mind wandering is like a form of light sleep that provides some of that state's learning benefits. To better understand whether mind wandering might compensate for lost sleep, Simor and his colleagues next plan to study narcolepsy and sleep deprivation. 'We know that people spend significant amounts of time not focused on what they are doing,' Smallwood says. 'The authors' work is important because it helps us understand how reasonably complex forms of behavior can continue when people are focused on other things—and that even though our thoughts were elsewhere, the external behavior can still leave its mark on the person.'
Yahoo
2 hours ago
- Yahoo
Antigen and Antibody Diagnostics Market to Reach USD 68 Billion by 2034, Driven by 4.6% CAGR Growth
Antigen and Antibody Diagnostics Market Outlook and Forecast to 2034 Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- Introduction: A Rapidly Evolving Diagnostic Ecosystem The global antigen and antibody diagnostics market is undergoing a significant transformation driven by rapid technological innovation, rising demand for quick and accurate disease detection, and expanding healthcare accessibility, particularly in emerging economies. Valued at approximately $43 billion in 2024, the market is forecasted to reach $68 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.6% during the forecast period. This expansion is reflective of broader healthcare trends, including the increasing need for point-of-care testing, advancements in artificial intelligence (AI) integration, and growing awareness about early diagnosis and disease monitoring. Download PDF Brochure: Drivers: Technology, Infrastructure, and Global Health Priorities One of the core growth catalysts is the evolution of point-of-care testing (POCT) technologies, which allow medical professionals to obtain results swiftly and accurately, often outside traditional laboratory environments. These innovations have proven vital in remote or resource-constrained regions and during public health emergencies such as the COVID-19 pandemic. The demand for portable, efficient, and user-friendly diagnostic devices has never been higher. Another pivotal driver is the growing prevalence of infectious diseases, including influenza, hepatitis, and emerging viral outbreaks. The urgent need for swift containment and response to such health threats accelerates the demand for antigen and antibody testing tools. Parallelly, global healthcare infrastructure development—especially across Asia-Pacific and parts of Latin America and Africa—continues to boost diagnostic adoption by improving laboratory networks, hospital capacity, and access to essential diagnostic services. Technology Integration: AI Enhancing Precision and Efficiency The integration of artificial intelligence (AI) into diagnostic platforms represents a transformative leap forward. AI-driven tools are increasingly used to enhance the accuracy and efficiency of test results, particularly in large-scale screening programs and high-throughput labs. These intelligent systems reduce human error, optimize workflow, and allow for real-time interpretation of complex data. As AI becomes a more integral part of diagnostics, it is enabling providers to deliver faster, more personalized healthcare services, thereby increasing adoption rates globally. Challenges: Regulatory, Financial, and Operational Hurdles Despite strong growth potential, the antigen and antibody diagnostics sector faces several challenges. Regulatory complexity remains a significant obstacle. Obtaining approval for new diagnostic technologies often involves lengthy, costly, and variable processes depending on the region. Smaller manufacturers may find it difficult to meet these regulatory demands, limiting innovation from emerging players. Moreover, the requirement for significant R&D investment poses a financial burden, especially on startups and mid-sized companies. The costs associated with developing, validating, and scaling new diagnostic tests are high, and coupled with pricing pressures in competitive markets, this can hinder profitability and sustainability. Supply chain vulnerabilities, exposed during the COVID-19 crisis, have also demonstrated how disruptions in raw material sourcing and logistics can delay product availability, strain manufacturing timelines, and escalate costs. Segmentation Overview: Understanding the Market Structure By Product Type Antibodies, particularly monoclonal antibodies, command the largest share (around 55%), playing a critical role in diagnosing cancers, autoimmune disorders, and various infectious diseases. Their precision and reliability make them invaluable tools in both clinical and research settings. Antigens represent approximately 40% of the market and are crucial for detecting pathogens in infections. The growing need for early diagnosis tools has led to a rise in antigen-based POCT devices. Assays and Kits, while making up the remaining 5%, provide essential supporting tools, especially in home diagnostics and research laboratories. By Technology ELISA (Enzyme-Linked Immunosorbent Assay) remains the gold standard in diagnostics, accounting for about 30% of the market due to its high sensitivity in detecting a wide range of diseases. Rapid Tests, with a market share of around 25%, are gaining popularity due to their ease of use and quick results. These are extensively used during health crises for mass screenings. Western Blotting and Lateral Flow Assays hold 10–15% and 20% market shares respectively, primarily used in confirmatory diagnostics for infections and autoimmune conditions. By Application Infectious Disease Diagnostics dominate the application segment, with a 40% market share. The continuous emergence of new pathogens ensures sustained demand. Cancer Diagnostics, leveraging antibody-based biomarker detection, account for 30%, with increasing focus on early detection and personalized treatment pathways. Autoimmune and Cardiovascular Disease Diagnostics are emerging areas, supported by rising incidence and innovations in biomarker research. By End User Hospitals and Diagnostic Laboratories are the principal end users, collectively representing 70% of the market, driven by their scale and resource availability. Research Institutions and POCT Facilities contribute around 15%, a figure expected to rise with increased funding and decentralized testing approaches. By Distribution Channel Direct Sales account for around 60%, preferred for their control and customization benefits. Distributors and Retailers, making up the remaining 40%, are essential in expanding geographic reach, particularly in rural and underserved markets. Browse full Report - Market Segmentation By Product Type Antigens Antibodies Other related products (e.g., assays, kits) By Technology ELISA Technology Rapid Tests Western Blotting Lateral Flow Assays By Application Infectious Diseases Cancer Diagnostics Autoimmune Disorders Cardiovascular Diseases Other Applications By End User Hospitals Diagnostic Laboratories Research Institutions Point-of-Care Testing (POCT) Locations By Distribution Channel Direct Sales Distributors and Retailers By Geography North America Europe Asia Pacific Latin America Middle East & Africa Regional Insights: Global Distribution and Growth Potential North America leads the global market with a 45% revenue share in 2024, thanks to a well-established healthcare system, strong regulatory frameworks, and high R&D expenditure. Europe follows, holding 30%, with a CAGR of 6.5% projected. The region benefits from collaborative research efforts, public health initiatives, and advanced diagnostic technologies. Asia-Pacific is the fastest-growing region, forecasted to grow at 8% CAGR through 2034. Rapid urbanization, rising middle-class incomes, and expanded healthcare access in countries like India and China are fueling market growth. Latin America and Middle East & Africa, while smaller in share (around 5% combined), offer high growth potential as investments in healthcare infrastructure and disease surveillance increase. Key Competitors Roche Diagnostics Abbott Laboratories Siemens Healthineers Thermo Fisher Scientific bioMérieux Ortho Clinical Diagnostics BD (Becton, Dickinson and Company) DiaSorin Hologic PerkinElmer Agilent Technologies Genomic Health (a part of Exact Sciences) Mindray Fujirebio Lonza Group Buy Now: Competitive Landscape: Strategic Moves Reshaping the Market Leading players such as Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific dominate the market through innovation, acquisitions, and global outreach. Company Name: Roche Diagnostics Month & Year: September 2023 Type of Development: Product Launch Detailed Analysis: Roche Diagnostics launched a new high-throughput antigen testing platform aimed at enhancing the efficiency of diagnostic testing in laboratories. This development is significant as it responds to the ongoing global demand for rapid and accurate diagnostics, particularly post-pandemic. The new platform promises improved sensitivity and specificity in detecting viral infections, thus providing healthcare professionals with reliable results faster. The introduction of such technology is likely to set new standards in the market, potentially pressuring competitors to innovate more aggressively. This could shift competitive dynamics, as companies pivot to ensure their products are equally adept at meeting these emerging standards of testing reliability and speed, leading to an increased focus on R&D investment across the industry. Company Name: Abbott Laboratories Month & Year: August 2023 Type of Development: Acquisition Detailed Analysis: Abbott Laboratories announced its acquisition of a leading biotech firm specializing in antibody development for diagnostic applications. This acquisition aligns with Abbott's strategic goal of enhancing its diagnostic portfolio. The integration of advanced biotechnology and proprietary methods from the acquired firm is expected to bolster Abbott's capabilities in antibody-based diagnostics. This move could influence market dynamics by consolidating Abbott's position as a leader in the diagnostic space, thus challenging other major players such as Roche and Siemens. With enhanced capabilities, Abbott may be able to offer more sophisticated testing solutions that can penetrate existing markets and attract new clientele, thereby reshaping consumer preferences and competitive threats in the industry. Company Name: Siemens Healthineers Month & Year: July 2023 Type of Development: Regulatory Approval Detailed Analysis: Siemens Healthineers received regulatory approval for its innovative antibody testing solution designed for autoimmune disorders. This marked a significant milestone for the company, as it expands its offerings in a specialized market segment. The approval not only reflects Siemens' commitment to innovation in diagnostics but also enhances its competitive edge against rivals trying to penetrate the growing autoimmune diagnostics market. The acceptance of this product can lead to increased market share for Siemens as healthcare providers increasingly focus on accurate diagnostic tools to improve patient outcomes. This development may incite competitive shifts, prompting other companies to expedite their R&D and seek similar regulatory approvals to maintain their market positions. Company Name: Hologic Month & Year: June 2023 Type of Development: Partnership Detailed Analysis: Hologic entered into a strategic partnership with a leading software company to develop advanced AI-driven diagnostic platforms. This partnership intends to combine Hologic's diagnostic expertise with cutting-edge AI technology to enhance diagnostic accuracy and operational efficiency. The significance of this partnership lies in its potential to revolutionize how diagnostic data is interpreted, shifting the industry towards more personalized medicine. As AI tools become integrated into diagnostic workflows, there may be a notable change in how healthcare providers make clinical decisions. This could create a competitive advantage for Hologic, attracting healthcare providers eager to leverage AI technologies, steering the market towards more technologically advanced solutions. Company Name: PerkinElmer Month & Year: May 2023 Type of Development: Expansion Detailed Analysis: PerkinElmer announced the expansion of its manufacturing facility to enhance production capabilities for antibodies used in various diagnostic applications. This expansion comes as a direct response to the increasing global demand for high-quality diagnostic tools, spurred by heightened awareness of preventive healthcare. The facility's upgrade aims to double the production output, thereby streamlining supply chains and reducing lead times for customers. This proactive approach positions PerkinElmer as a major player capable of meeting market demand amidst rising competition. The strategic expansion not only solidifies PerkinElmer's commitment to quality and accessibility in diagnostics but also signals broader market trends towards scalability and responsiveness in manufacturing processes within the diagnostic industry. This report is also available in the following languages : Japanese (診断市場向け抗原・抗体), Korean (진단용 항원 및 항체 시장), Chinese (诊断市场用抗原和抗体), French (Antigènes et anticorps pour le marché du diagnostic), German (Antigene und Antikörper für den Diagnostikmarkt), and Italian (Antigene e anticorpi per il mercato diagnostico), etc. Request Sample Pages: More Research Finding – Glow Cell Assay Reagents Market The global Glow Cell Assay Reagents market is valued at approximately $980 million in 2024, with a projected market value reaching around $1.95 billion by 2034. This growth trajectory reflects a robust Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period from 2025 to 2034. Microbubble Contrast Media Market The global microbubble contrast media market is projected to reach approximately $650 million by the end of 2024, driven by the growing demand for enhanced imaging techniques in diagnostic procedures. The market is expected to witness substantial growth over the forecast period from 2025 to 2034, with a projected market value of around $1.2 billion by 2034. Cancer Nanomedicine Market The cancer nanomedicine market is valued at approximately $72 billion in 2024, with an anticipated growth trajectory that will elevate its market value to around $150 billion by 2034. This reflects a Compound Annual Growth Rate (CAGR) of approximately 7.6% during the forecast period from 2025 to 2034. Cycloplegic Agents Market The global cycloplegic agents market is valued at approximately $1.2 billion in 2024, with a forecasted growth trajectory anticipated to reach around $1.8 billion by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 4.1% for the period from 2025 to 2034. Gastroesophageal Reflux Therapeutic Instrument Market The gastroesophageal reflux (GER) therapeutic instrument market is projected to reach a value of approximately $3.5 billion in 2024, driven by increasing prevalence of gastroesophageal reflux disease (GERD) and advancements in therapeutic technologies. Over the forecast period from 2025 to 2034, this market is expected to grow at a robust Compound Annual Growth Rate (CAGR) of 6.2%, projecting a market value of about $6.5 billion by 2034. Mobile G-arm Market The global mobile G-arm market is valued at approximately $1.5 billion in 2024, driven by the increasing adoption of advanced imaging technologies in surgical and diagnostic procedures. The market is expected to reach around $2.8 billion by 2034, reflecting a compound annual growth rate (CAGR) of 6.7% during the forecast period from 2025 to 2034. Sports Medicine Consumables Market The global sports medicine consumables market is valued at approximately $6.5 billion in 2024, with projections indicating significant growth, potentially reaching $11.2 billion by 2034. This growth trajectory translates to a Compound Annual Growth Rate (CAGR) of around 6.5% over the forecast period from 2025 to 2034. Full Automatic Nucleic Acid Detection Analyzer Market The global market for Full Automatic Nucleic Acid Detection Analyzers is poised to reach an estimated value of $2.5 billion in 2024, driven by increasing demand for precise diagnostic tools in healthcare. The market is projected to expand significantly over the forecast period from 2025 to 2034, with a predicted market value of approximately $4.8 billion. This growth represents a Compound Annual Growth Rate (CAGR) of around 8.4%. Fetal Magnetic Resonance Imaging System Market The global fetal magnetic resonance imaging (fMRI) system market is valued at approximately $150 million. This innovative imaging technology is essential for prenatal diagnostics, providing non-invasive insights into fetal development. The market is projected to reach around $350 million by 2034, driven by advancements in MRI technology and increasing awareness of prenatal health. Doppler Diagnosis System Market The global market for Doppler diagnosis systems is valued at approximately $1.2 billion in 2024, driven by advancements in diagnostic imaging technology and increasing demand for non-invasive procedures. Looking ahead, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5%, potentially reaching around $2.2 billion by 2034. Vacuum Assisted Biopsy Equipment Market The global vacuum-assisted biopsy (VAB) equipment market is valued at approximately $1.2 billion in 2024, with projections indicating a market growth to around $2.5 billion by 2034. This represents a robust Compound Annual Growth Rate (CAGR) of approximately 7.7% during the forecast period from 2025 to 2034. Urodynamic Analyzer Market The global urodynamic analyzer market is valued at approximately $450 million, with a robust growth trajectory anticipated over the next decade. Projections indicate that the market will reach about $800 million by 2034, reflecting a Compound Annual Growth Rate (CAGR) of roughly 6.2% from 2025 to 2034. Urodynamic Manometer Market The global urodynamic manometer market is estimated to reach a value of approximately $350 million in 2024, driven by increasing prevalence of urinary disorders and a rising geriatric population that requires reliable diagnostic tools. The market is projected to grow significantly, with a forecasted value of around $550 million by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 4.7% during the period from 2025 to 2034. Disposable Uterine Probe Market The disposable uterine probe market is projected to achieve a value of approximately $150 million in 2024, with a robust growth trajectory anticipated through the forecast period of 2025 to 2034, reaching an estimated market value of around $450 million. This represents a Compound Annual Growth Rate (CAGR) of about 12.5%. Disposable Injection Needle for Endoscope Market The disposable injection needle market for endoscopy is valued at approximately $500 million in 2024, driven by an increasing prevalence of gastrointestinal diseases and a growing demand for minimally invasive procedures. The market is projected to reach around $1.2 billion by 2034, reflecting significant opportunities within the healthcare sector as technological advancements improve the efficacy of endoscopic tools. Coagulation Controls Market The global coagulation control market is valued at approximately $3.2 billion in 2024 and is projected to reach around $5.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 6.5% during the forecast period from 2025 to 2034. Iomeprol Injection Market The global market for Iomeprol Injection is valued at approximately $320 million, driven by increasing demand for advanced imaging diagnostics and enhanced patient safety measures. The market is projected to expand at a CAGR of 6.5% from 2025 to 2034, potentially reaching around $651 million by the end of the forecast period. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data